Stock Track | GENSCRIPT BIO Soars 6.61% Intraday on Strong CARVYKTI Sales and Upcoming Interim Results

Stock Track

Aug 10

GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.

The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.

The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1135232444"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135232444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135232444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135232444","market":"sg","top_or_hot":-1,"title":"Stock Track | GENSCRIPT BIO Soars 6.61% Intraday on Strong CARVYKTI Sales and Upcoming Interim Results","media":"Stock Track","content":"<p>GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.</p><p>The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.</p><p>The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GENSCRIPT BIO Soars 6.61% Intraday on Strong CARVYKTI Sales and Upcoming Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GENSCRIPT BIO Soars 6.61% Intraday on Strong CARVYKTI Sales and Upcoming Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-10 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.</p><p>The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.</p><p>The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1135232444","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135232444","pubTimestamp":1786325673,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"股票跟踪 | 由于汽车销售强劲和即将公布的中期业绩，金斯瑞生物盘中飙升 6.61%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}